DR. REDDY'S LABORATORIES-ADR(NYSE:RDY) stock News

RDY Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill

Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria

8 days ago - By: Benzinga - Mentions: AMPH TEVA AMRX VTRS

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

17 days ago - By: Zacks Investment Research - Mentions: TEVA ALVO

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

a month ago - By: Zacks Investment Research - Mentions: TEVA ALVO

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

3 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q1FY26 Financial Results

3 months ago - By: Yahoo Finance - Mentions: ALVO

Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement

4 months ago - By: Yahoo Finance - Mentions: JPM RELI OMI SMLR ...

JPMorgan Backs RIL Despite Margin Pressures

4 months ago - By: Yahoo Finance - Mentions: OMI SMLR RNXT HUM ...

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

4 months ago - By: Benzinga - Mentions: JNJ MRK ALVO

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

4 months ago - By: Zacks Investment Research - Mentions: MRK AMGN ALVO

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

4 months ago - By: Dr. Reddy’s Laboratories Ltd. - Mentions: ALVO

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

4 months ago - By: Alvotech - Mentions: ALVO SDB

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

5 months ago - By: Zacks Investment Research - Mentions: ALLO ALVO

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

5 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

6 months ago - By: Zacks Investment Research - Mentions: TEVA

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

6 months ago - By: Yahoo Finance - Mentions: AAPL MSFT

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

7 months ago - By: Zacks Investment Research - Mentions: JNJ AMGN ALVO

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

7 months ago - By: Bio-Thera Solutions, Ltd

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

7 months ago - By: Dr. Reddy’s Laboratories Ltd. - Mentions: ALVO

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

7 months ago - By: Alvotech - Mentions: ALVO

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

7 months ago - By: Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

8 months ago - By: Henlius

DR. REDDY'S LABORATORIES-ADR (RDY) Stock News

RDY Latest News, Press Relases and Analysis

Dr. Reddy's Laboratories-ADR (NYSE:RDY) Meets Key Peter Lynch Investment Criteria

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

Here's How Alvotech is Expanding its Portfolio Beyond Immunology

ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Dr. Reddy’s Q1FY26 Financial Results

Dr. Reddy’s Laboratories (RDY) and Alvotech Enter Into a Collaboration and License Agreement

JPMorgan Backs RIL Despite Margin Pressures

Owens & Minor and Rotech Healthcare Agree to End Previously Planned Acquisition

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA